{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:31:19Z","timestamp":1783467079249,"version":"3.55.0"},"reference-count":38,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Cachexia, a disorder associated with anorexia, inflammation, and muscle wasting, is frequent in cancer patients. We performed post\u2010hoc analyses of the ONO\u20107643\u201004 study to investigate the efficacy and safety of anamorelin in subgroups of Japanese patients with non\u2010small cell lung cancer (NSCLC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The patients were divided into subgroups by baseline characteristics, including sex, age, body mass index, prior weight loss, performance status (PS), concomitant anticancer therapy, and number of previous chemotherapy regimens. The changes from baseline through to 12\u2009weeks for lean body mass (LBM), body weight, and appetite were calculated. Appetite was evaluated using the quality of life questionnaire for cancer patients treated with anticancer drugs (QOL\u2010ACD) item 8 score. Responder rates were defined as the maintenance\/improvement of LBM (\u22650\u00a0kg), body weight (\u22650\u00a0kg), or QOL\u2010ACD item 8 score (\u22650) from baseline to all evaluation time points. Safety was evaluated in patients subgrouped by age and PS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Anamorelin resulted in greater improvements versus placebo in LBM, body weight, and appetite in most subgroups. Anamorelin was also associated with greater LBM, body weight, and appetite responder rates than placebo in nearly all subgroups. Among anamorelin\u2010treated patients, adverse drug reactions (ADRs) tended to be more frequent with increasing age (&lt;65\u2009years, 19.2%; \u226565 to &lt;75\u2009years, 45.9%; \u226575\u2009years, 60.0%) and PS score (PS 0\u20131, 38.4%; PS 2, 60.0%). The frequency of serious ADRs was 2.7% and 0% in the PS 0\u20131 and PS 2 subgroups, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study of NSCLC patients with cancer cachexia revealed consistent improvements in LBM, body weight, and appetite across most subgroups of anamorelin\u2010treated patients. This study also demonstrated the tolerability of anamorelin regardless of age and PS, with a low incidence of serious ADRs in each subgroup.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.5206","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T08:00:14Z","timestamp":1668672014000},"page":"2918-2928","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Efficacy and safety of anamorelin in patients with cancer cachexia: Post\u2010hoc subgroup analyses of a placebo\u2010controlled study"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7723-8960","authenticated-orcid":false,"given":"Koichi","family":"Takayama","sequence":"first","affiliation":[{"name":"Department of Pulmonary Medicine, Graduate School of Medical Science Kyoto Prefectural University of Medicine  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Takiguchi","sequence":"additional","affiliation":[{"name":"Clinical Development Planning Ono Pharmaceutical Co., Ltd.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Komura","sequence":"additional","affiliation":[{"name":"Clinical Development Planning Ono Pharmaceutical Co., Ltd.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4047-2929","authenticated-orcid":false,"given":"Tateaki","family":"Naito","sequence":"additional","affiliation":[{"name":"Division of Thoracic Oncology Shizuoka Cancer Center  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70218-7"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2012.209"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2014.09.008"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v7.i4.17"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2008.06.013"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00624-w"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100092"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00611"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/45230"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031768"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.12.8111"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1500447"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.1041500"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.14"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13539-014-0159-5"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1500-1"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-5-594"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2008.12.003"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00558-6"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31128"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3144-z"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32406"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12675"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1611(199907\/08)8:4<355::AID-PON401>3.0.CO;2-I"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015614505929"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12391"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14734"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1950411"},{"key":"e_1_2_13_30_1","unstructured":"Adlumiz\u00ae (Anamorelin) Common Technical Document 2011. Available at:https:\/\/www.pmda.go.jp\/drugs\/2021\/P20210113006\/180188000_30300AMX00003_K100_1.pdf[In Japanese]. Last accessed October 4 2021."},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-010-1075-7"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2606-z"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-020-0704-8"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30678-3"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.095"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211006182"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.7180"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/1534735420988343"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34154"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.5206","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.5206","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.5206","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T08:19:28Z","timestamp":1732522768000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.5206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1002\/cam4.5206"],"URL":"https:\/\/doi.org\/10.1002\/cam4.5206","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,16]]},"assertion":[{"value":"2021-12-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}